Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ametinib Combined With Bevacizumab in First-line Treatment of Non-oligometastatic Advanced NSCLC With EGFR-mutations.

NCT05754736 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Shandong First Medical University as lead sponsor.

NCT NCT05754736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05754736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ametinib Combined With Bevacizumab in First-line Treatment of Non-oligometastatic Advanced NSCLC With EGFR-mutations.
Lead sponsor
The Second Affiliated Hospital of Shandong First Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2022
Completion date
December 1, 2025
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer